Hospital
Main Line Hospitals, INC.
Main Line Hospitals, INC. was paid $4.52M by Medicaid between Oct 2018 and Dec 2024, across 65 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoMAIN LINE HOSPITALS, INC.
BRYN MAWR, PA 19010
BRYN MAWR, PA 19010
33aNPI1508971441assigned 08/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.52M
24GClaims45,988
24DCodes billed65
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#65 of 154
Median peer was paid$2.82M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36 | $3K | |
| 2019 | 84 | $767.76 | |
| 2020 | 3,944 | $298K | |
| 2021 | 14,485 | $1.37M | |
| 2022 | 5,604 | $974K | |
| 2023 | 11,335 | $1.14M | |
| 2024incomplete | 10,500 | $746K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 9,314 | 9,020 | $2.14M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 8,523 | 8,215 | $1.79M |
| G0378 | Hospital observation service, per hour | 5.3% | 179 | 172 | $238K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 348 | 343 | $71K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.4% | 386 | 364 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 502 | 464 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 100 | 94 | $23K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 123 | 118 | $20K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 165 | 159 | $17K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 113 | 113 | $12K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,950 | 4,588 | $10K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 476 | 460 | $8K |
53 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 321 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,350 | $7K |
| 76830 | Ultrasound, transvaginal | <1% | 71 | $6K |
| 76801 | <1% | 55 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 123 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 801 | $5K |
| 64483 | <1% | 18 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 354 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 202 | $4K |
| 80053 | Comprehensive metabolic panel | <1% | 1,490 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 226 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,285 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 749 | $3K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 53 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 737 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 33 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 232 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 206 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,034 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 15 | $1K |
| 84703 | <1% | 374 | $1K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 41 | $1K |
| 76813 | <1% | 12 | $1K | |
| 85027 | <1% | 147 | $1K | |
| 73564 | <1% | 26 | $1K | |
| 86900 | <1% | 126 | $797.12 | |
| 76642 | <1% | 13 | $752.07 | |
| 71045 | Radiologic examination, chest; single view | <1% | 328 | $602.69 |
| 84484 | <1% | 508 | $596.80 | |
| 81001 | <1% | 414 | $485.49 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35 | $374.14 |
| 82248 | <1% | 63 | $366.75 | |
| 83690 | <1% | 208 | $325.33 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 27 | $268.94 |
| 85610 | <1% | 128 | $246.65 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 124 | $240.38 |
| 85730 | <1% | 57 | $222.23 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 656 | $76.31 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,377 | $36.91 |
| 81003 | <1% | 38 | $31.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 863 | $26.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 235 | $4.30 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 50 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 29 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 28 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 301 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 171 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 279 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 418 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 63 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 275 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEHRLICH, LEIGH (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Main Line Hospitals, INC. | Wynnewood, PA | $17.19M |
| Riddle Memorial Hospital | Media, PA | $4.78M |
| Main Line Hospitals, INC. | Paoli, PA | $2.60M |
| Main Line Hospitals, INC. | Wynnewood, PA | $368K |
| Main Line Hospitals, INC. | Malvern, PA | $272K |
| Main Line Hospitals, INC. | Broomall, PA | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.